Ligang Xing

机构：Shandong University, Kanagawa Prefectural Hospital Organization, Shandong Tumor Hospital, Shandong First Medical University · ORCID：0000-0002-0528-9048

发表论文 207 篇 · 总被引 4330 次 · h-index 36

代表论文

• Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer (2025 · Journal of Clinical Oncology · 被引 76)
• Phase I/II clinical trial of efficacy and safety of EGCG oxygen nebulization inhalation in the treatment of COVID-19 pneumonia patients with cancer (2024 · BMC Cancer · 被引 38)
• A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation. (2024 · Journal of Clinical Oncology · 被引 20)
• Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials (2025 · 癌症：英文版 · 被引 12)
• OA04.06 Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001) (2024 · Journal of Thoracic Oncology · 被引 12)
• Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases (2024 · BMC Cancer · 被引 11)